

Our Ref: 302/2023  
JULY 2023

## Re: Your request made under the Freedom of Information Act 2000

I have a freedom of information query regarding the treatment for Myelofibrosis. Could you please answer the following questions:

Q1. Does your trust treat myeloproliferative neoplasms? If not, which other trust do you refer these patients to?

YES

. Please provide the total number of patients treated in the last 6 months for:

- Polycythaemia Vera (ICD10 code D45)

Answer: 82

- Myelofibrosis (ICD10 code D47.4)

Answer: 8

- Myelofibrosis (ICD10 code D47.4) patients aged 65 and older

Answer: 7

How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years?

Answer: 38

Q3. How many patients were treated in the past 6 months (for any disease) with:

- Ruxolitinib 13
- Fedratinib 0

Q4. Of the patients treated in the past 6 months with Ruxolitinib, how many patients had a diagnosis for:

- Polycythaemia Vera (ICD10 code D45)
- Myelofibrosis (ICD10 code D47.4)

Our pharmacy system doesn't store diagnosis data, so we're unable to determine this against the prescribed treatment. To ascertain this data, the Trust would need to perform an audit of each individual patient record, which wouldn't be achievable within the s.12 timescale of the Freedom of Information Act 2000.

Q5. How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years?

- Of these patients, how many were treated in the past 6 months with Hydroxycarbamide?
- Of these patients, how many were treated in the past 6 months with Interferon therapy?
- Of these patients, how many have received no active treatment in the past 6 months?

Our pharmacy system doesn't store diagnosis data, so we're unable to determine this against the prescribed treatment. To ascertain this data, the Trust would need to perform an audit of each individual patient record, which wouldn't be achievable within the s.12 timescale of the Freedom of Information Act 2000.

Our Ref: 302/2023  
JULY 2023